Anna Mae Diehl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Mae Diehl has a total of 282 co-authors. Here are the top co-authors by number of shared publications:
Steve S. Choi
Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, U.S.A.
24 shared publications- Alessia Omenetti
Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC
19 shared publications Guanhua Xie
17 shared publications- Thiago Almeida Pereira
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, United States
15 shared publications Cynthia D. Guy
14 shared publications- Manal F. Abdelmalek
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
11 shared publications
Latest Publications
- Open Access
- 10 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
- 10 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Open AccessConcordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
- Open Access
- 15 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16354
Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit
Harmful algal bloom toxin microcystin has been associated with metabolic dysfunction-associated steatotic liver disease (MASLD) progression and hepatocellular carcinoma, though the mechanisms remain unclear. Using an established mouse model of MASLD, we show that the NLRP3–Hsp70–TLR4 axis drives in part the inflammation of the liver lobule that results in the progression of MASLD to metabolic dysfunction-associated steatohepatitis (MASH). Results showed that mice deficient in NLRP3 exhibited decreased MASH pathology, blocked Hsp70 expression, and co-binding with NLRP3, a crucial protein component of the liver inflammasome. Hsp70, both in the liver lobule and extracellularly released in the liver vasculature, acted as a ligand to TLR4 in the liver, primarily in hepatocytes to activate the NF-κB pathway, ultimately leading to hepatic cell death and necroptosis, a crucial pathology of MASH progression. The above studies show a novel insight into an inflammasome-triggered Hsp70-mediated inflammation that may have broader implications in MASLD pathology. MASLD to MASH progression often requires multiple hits. One of the mediators of progressive MASLD is environmental toxins. In this research report, we show for the first time a novel mechanism where microcystin-LR, an environmental toxin, advances MASLD to MASH by triggering the release of Hsp70 as a DAMP to activate TLR4-induced inflammation in the liver.
- 15 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (22) , 16354
Open AccessHepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit
Harmful algal bloom toxin microcystin has been associated with metabolic dysfunction-associated steatotic liver disease (MASLD) progression and hepatocellular carcinoma, though the mechanisms remain unclear. Using an established mouse model of MASLD, we show that the NLRP3–Hsp70–TLR4 axis drives in part the inflammation of the liver lobule that results in the progression of MASLD to metabolic dysfunction-associated steatohepatitis (MASH). Results showed that mice deficient in NLRP3 exhibited decreased MASH pathology, blocked Hsp70 expression, and co-binding with NLRP3, a crucial protein component of the liver inflammasome. Hsp70, both in the liver lobule and extracellularly released in the liver vasculature, acted as a ligand to TLR4 in the liver, primarily in hepatocytes to activate the NF-κB pathway, ultimately leading to hepatic cell death and necroptosis, a crucial pathology of MASH progression. The above studies show a novel insight into an inflammasome-triggered Hsp70-mediated inflammation that may have broader implications in MASLD pathology. MASLD to MASH progression often requires multiple hits. One of the mediators of progressive MASLD is environmental toxins. In this research report, we show for the first time a novel mechanism where microcystin-LR, an environmental toxin, advances MASLD to MASH by triggering the release of Hsp70 as a DAMP to activate TLR4-induced inflammation in the liver.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
358 - Statin Use and Liver Injury in Nonalcoholic Fatty Liver Disease: Results of a Paired Clinical and Gene Expression Profile Analysis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
358 - Statin Use and Liver Injury in Nonalcoholic Fatty Liver Disease: Results of a Paired Clinical and Gene Expression Profile Analysis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
21 - YAP1-Dependent Induction of IGF2BP3 Reprograms Hepatocytes into Stem-Like Cells During Liver Regeneration
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
21 - YAP1-Dependent Induction of IGF2BP3 Reprograms Hepatocytes into Stem-Like Cells During Liver Regeneration
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-166-166
808 - Hedgehog Signaling Directly Regulates Metabolism and Proliferation in Hepatocytes and is Critical for Normal Liver Regeneration Following Partial Hepatectomy in Mice
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-166-166
808 - Hedgehog Signaling Directly Regulates Metabolism and Proliferation in Hepatocytes and is Critical for Normal Liver Regeneration Following Partial Hepatectomy in Mice
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
831 - Epithelial-Stromal Signaling in Fibrolammelar Hepatocelular Carcinoma
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
831 - Epithelial-Stromal Signaling in Fibrolammelar Hepatocelular Carcinoma
- 20 March 2018
- Published by Taylor & Francis in Critical Reviews in Biochemistry and Molecular Biology
- Vol. 53 (3) , 264-278
The hedgehog pathway in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of obesity-associated liver diseases and it has become the major cause of cirrhosis in the Western world. The high prevalence of NAFLD-associated advanced liver disease reflects both the high prevalence of obesity-related fatty liver (hepatic steatosis) and the lack of specific treatments to prevent hepatic steatosis from progressing to more serious forms of liver damage, including nonalcoholic steatohepatitis (NASH), cirrhosis, and primary liver cancer. The pathogenesis of NAFLD is complex, and not fully understood. However, compelling evidence demonstrates that dysregulation of the hedgehog (Hh) pathway is involved in both the pathogenesis of hepatic steatosis and the progression from hepatic steatosis to more serious forms of liver damage. Inhibiting hedgehog signaling enhances hepatic steatosis, a condition which seldom results in liver-related morbidity or mortality. In contrast, excessive Hh pathway activation promotes development of NASH, cirrhosis, and primary liver cancer, the major causes of liver-related deaths. Thus, suppressing excessive Hh pathway activity is a potential approach to prevent progressive liver damage in NAFLD. Various pharmacologic agents that inhibit Hh signaling are available and approved for cancer therapeutics; more are being developed to optimize the benefits and minimize the risks of inhibiting this pathway. In this review we will describe the Hh pathway, summarize the evidence for its role in NAFLD evolution, and discuss the potential role for Hh pathway inhibitors as therapies to prevent NASH, cirrhosis and liver cancer.
- 20 March 2018
- Published by Taylor & Francis in Critical Reviews in Biochemistry and Molecular Biology
- Vol. 53 (3) , 264-278
The hedgehog pathway in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of obesity-associated liver diseases and it has become the major cause of cirrhosis in the Western world. The high prevalence of NAFLD-associated advanced liver disease reflects both the high prevalence of obesity-related fatty liver (hepatic steatosis) and the lack of specific treatments to prevent hepatic steatosis from progressing to more serious forms of liver damage, including nonalcoholic steatohepatitis (NASH), cirrhosis, and primary liver cancer. The pathogenesis of NAFLD is complex, and not fully understood. However, compelling evidence demonstrates that dysregulation of the hedgehog (Hh) pathway is involved in both the pathogenesis of hepatic steatosis and the progression from hepatic steatosis to more serious forms of liver damage. Inhibiting hedgehog signaling enhances hepatic steatosis, a condition which seldom results in liver-related morbidity or mortality. In contrast, excessive Hh pathway activation promotes development of NASH, cirrhosis, and primary liver cancer, the major causes of liver-related deaths. Thus, suppressing excessive Hh pathway activity is a potential approach to prevent progressive liver damage in NAFLD. Various pharmacologic agents that inhibit Hh signaling are available and approved for cancer therapeutics; more are being developed to optimize the benefits and minimize the risks of inhibiting this pathway. In this review we will describe the Hh pathway, summarize the evidence for its role in NAFLD evolution, and discuss the potential role for Hh pathway inhibitors as therapies to prevent NASH, cirrhosis and liver cancer.
- 1 March 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68 (3) , 550-562
Hedgehog signalling in liver pathophysiology
- 1 March 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68 (3) , 550-562
Hedgehog signalling in liver pathophysiology
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1073
RNA-Binding Protein IGF2BP3 Regulates Cell Fate Decisions that Drive Cirrhosis Pathogenesis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1073
RNA-Binding Protein IGF2BP3 Regulates Cell Fate Decisions that Drive Cirrhosis Pathogenesis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S559
Hedgehog-Dependent yap Signaling Activates Serine Biogenesis and Glutaminolysis to Promote Hepatic Stellate Cell Transdifferentiation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S559
Hedgehog-Dependent yap Signaling Activates Serine Biogenesis and Glutaminolysis to Promote Hepatic Stellate Cell Transdifferentiation